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Background: The balance between T helper cells Th2- and Th1-related cytokines plays a key role in multiple
sclerosis (MS). A shift from a Th1 towards a Th2 cytokine profile could have a beneficial effect on the clinical course
of the disease. The objective of this study was to assess Th2/Th1 cytokine profile in relapsing-remitting MS (RRMS)
patients receiving an immunosuppressive treatment with natalizumab (NAT), or an immunomodulatory treatment
with glatiramer acetate (GA) after one year of treatment.
Methods: This was an observational cross-sectional study. All consecutive patients diagnosed with RRMS who had
received GA or NAT for 12 months were included in the study. We determined serum levels of Th1 and Th2
cytokines (interleukin [IL]-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, monocyte chemotactic protein
[MCP]-1, tumor-necrosis factor [TNF]-α, interferon [IFN]-γ and granulocyte macrophage colony stimulating factor
[GM-CSF]) by flow cytometry. Th2/Th1 bias was defined based on the ratio of IL-4, IL-5, IL-6 or IL-10 Th2 cytokines
and proinflammatory INF-γ or TNF-α Th1 cytokines.
Results: Eleven patients under treatment with NAT and 12 patients treated with GA were evaluated. RRMS patients
treated with NAT showed significantly higher levels of IL-6 (p < 0.05), MCP-1 (p < 0.01), and GM-CSF (p < 0.05)
compared to GA patients after one year of treatment. A trend for increasing of IL-12p70, IL-1b, TNF- α and IFN- γ
levels was also found in patients receiving NAT compared to GA patients. IL-4/IFN-γ, IFN-γ/TNF-α and IL-10/IFN-γ
ratios as markers of Th2/Th1 ratio were significantly elevated in GA patients compared to those receiving NAT
(p < 0.05).
Conclusion: In conclusion, our findings suggest that GA promotes a superior Th2-biased anti-inflammatory
response as compared with NAT in the systemic circulation of RRMS patients. Future studies with larger cohorts will
determine whether this immune Th2 shift in GA patients is associated with a beneficial effect on disease outcome.
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Multiple sclerosis (MS) is an inflammatory demyelinating
disease of the central nervous system (CNS). T helper
(Th) cells appear to play a pivotal role in the autoreactive
immune response of the CNS in MS, primarily character-
ized by inflammation and demyielination [1,2]. Cytokines* Correspondence: orejacbn@gmail.com
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distribution, and reproduction in any mediumare key factors in the regulation of inflammatory
responses and may reflect the disease process in MS
[3,4]. Th cells can be divided into subtypes based on the
characteristic cytokine secretion patterns and their ef-
fector functions. While Th2-related cytokines such as
interleukin IL-4, IL-10, or IL-5 have been associated with
inflammation reduction and improvement of symptoms
in MS patients, Th1 cytokines such as interferon-gamma
(INF-γ) and tumor necrosis factor-alpha (TNF-α) have
been shown to increase inflammation, therefore leading
to disease progression and worsening of symptoms
[5-10]. Th2 and Th1 cytokines can cross-inhibit eachCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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balance between both types of cytokines. Induction of
Th1 cytokines toward Th2 could achieve the suppression
of undesirable autoimmunity and have a beneficial effect
on the clinical course of the disease [11]. In this scenario,
effective treatments should induce a shift toward Th2
cytokine anti-inflammatory response.
Treatment of relapsing-remitting MS (RRMS) with gla-
tiramer acetate (GA) (CopaxoneW) reduces frequency of
relapses and the appearance of new lesions in gadolinium
enhanced magnetic resonance imaging (MRI) [12,13]. As
other immunomodulatory treatments, GA seems to inter-
fere with the Th1/Th2 balance by promoting a shift from
the Th1 to the Th2 anti-inflammatory cytokine pathway
[14-22]. Natalizumab (NAT) (TysabriW), a humanized
monoclonal antibody against very late activation antigen
(VLA)-4 on leukocytes, has demonstrated to reduce the
relapse rate by about 70% in RRMS patients [23,24]. The
widely proposed mode of action of NAT is based on the
reduction of transmigration of leukocytes into the CNS
[25,26]. However, other immunological effects may also be
operative accounting for changes of some Th1/Th2 cyto-
kines levels in plasma of RRMS patients treated with NAT
[27,28].
In the present study, we aimed to evaluate the patterns
of Th2/Th1 cytokines in RRMS patients receiving an im-
munosuppressive treatment with NAT, or an immuno-
modulatory treatment with GA after one year of
treatment.
Methods
The present study was a cross-sectional, observational
study conducted at a University Hospital. Written
informed consent was obtained from all patients before
they were included in the study. The study was approved
by the Ethics Committee of the University Hospital La
Paz, Madrid.
Patients
All consecutive patients diagnosed with RRMS who had
received GA (CopaxoneW) or NAT (TysabriW) for
12 months were included in the study. All patients ful-
filled the McDonald criteria for RRMS [29]. Patients
underwent a complete neurological examination to
quantify patients’ disability by the Kutzke's Expanded
Disability Status Scale (EDSS) every 6 months. All
patients treated with NAT had been previously treated
with immunomodulatory treatments (GA or β-
interferon; minimum wash-out period of 1 month). The
GA-treated patients were naïve for previous treatments.
Cytokine analysis
Briefly, blood samples were collected from patients after
12 months of treatment and serum was obtained bycentrifugation and stored at −80°C until cytokine deter-
mination. All samples were collected before each drug
administration.
Serum levels of Th1- and Th2-related, MS-relevant
cytokines (interleukin [IL]-1a, IL-1b, IL-2, IL-4, IL-5, IL-6,
IL-8, IL-10, IL-12p70, IL-13, monocyte chemotactic pro-
tein [MCP]-1, tumor-necrosis factor [TNF]-α, interferon
[IFN]-γ and granulocyte macrophage colony stimulating
factor [GM-CSF]) were determined by flow cytometry
(FacsCalibur, BD Biosciense, CA, USA) using CBA Flex
Set kit (BD Bioscience, Bedford, MA, USA) following
manufacturer’s instructions. CBA Flex Set analysis was
performed using FCAP array v1.0 software (Soft Flow Inc.,
USA). Protein values were converted to NIBSC/WHO
protein standards for further comparisons.
Statistical analysis
Median serum cytokines levels between GA-treated
patients and those receiving NAT were compared using
Student´s t-test.
Th2/Th1 ratio was defined based on the ratio of IL-4,
IL-5, IL-6 or IL-10 Th2-related cytokines and proinflam-
matory INF-γ or TNF-α Th1-related cytokines. The me-
dian Th2/Th1 ratio was calculated for each group. The
non-parametric Mann-Whitney U test was performed in
order to compare both groups using GraphPad Prism
5.0 software (San Diego, CA, USA), and t-test under log
transformation of Th2/Th1 ratio is presented.
Results
Patient characteristics
A total of 23 RRMM patients treated with GA or NAT
for 12 months were included in the study. Eleven
patients under treatment with NAT and 12 patients trea-
ted with GA were evaluated.
The study population was comprised by 9 females in
each group (82% and 75% in NAT and GA group, re-
spectively) and 2 and 3 males (18% and 25%) in NAT
and GA group, respectively. The mean age was
37.73 ± 7.24 and 37.67 ± 10.58 years old for NAT and
GA-treated patients correspondingly.
Mean disease duration for patients treated with NAT
and GA was 7.90 ± 3.42 and 4.25 ± 2.70 years, respect-
ively. The mean EDSS score at the start of treatment
ranged from 0 to 6.50 for all patients, with a mean of
4.05 ± 1.67 in NAT-treated patients and 1.67 ± 1.77 in
those receiving GA (p = 0.005). After 12 months of treat-
ment, mean EDSS decreased by 0.2 and 0.1 in the NAT
and GA groups, respectively.
Th1/Th2 cytokine profile
Overall, patients receiving NAT showed significantly
higher levels of proinflammatory cytokines IL-6 (p< 0.05),
MCP-1 (p< 0.01) and GM-CSF (p< 0.05) compared to
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levels of IL-6, MCP-1 and GM-CSF in NAT patients were
5.21 pg/L (3.80-6.36), 121.23 pg/L (95.86-157.68) and
4.05 pg/L (1.38-12.19), respectively, whereas GA patients
showed median levels of 2.88 pg/L (1.05-5.75), 65.41 pg/L
(41.70-75.89) and 1.56 pg/L (0.68-3.23) for IL-6, MCP-1
and GM-CSF, respectively. Moreover, serum levels of
Th1-related cytokines IL-12p70, IL-1b, TNF-α, and IFN-γ
showed a clear tendency to be higher in patients receiving
NAT as compared to GA patients (Figure 1).
IL-4/IFN-γ, IL-4/TNF-α and IL-10/IFN-γ ratio as mar-
kers of Th2/Th1 ratio were significantly higher for GA-
treated patients as compared to those receiving NAT
after one year of treatment (p < 0.05) (Figure 2).
Discussion
The results of the present study suggest a Th2/Th1 bal-
ance shift in favour of a Th2 cytokine profile on GA-
treated patients, while NAT causes a predominant
Th1-biased response. This superior anti-inflammatoryA  
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Figure 1 Serum levels of cytokines after one year of treatment with G
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NAT group. *p < 0.05; **p < 0.01. GA= glatiramer acetate; NAT = natalizumabshift of GA seems to be mainly mediated by raising IL-4
and IL-10 levels which could lead to a down-regulation
of Th1 cytokine secretion. Accordingly, the enhance-
ment of circulating IL-4 and IL-10 and the subsequent
detrimental effect on IFN-γ and TNF-α seen in GA-
treated RRMS patients may play a protective role from
inflammatory response that could affect the clinical
course of disease in these patients. In this regard, a
stabilization of disability score was found in both NAT
and GA patients after one year of treatment. The poten-
tial clinical implications of immune response in GA-
treated patients have been previously assessed [30-32].
Indeed, Valenzuela et al. [31] reported an increased
IL-4/IFN-γ ratio to be associated with a favourable clin-
ical outcome in a study of 36 RRMS patients treated
with GA. However, the available findings suggesting the
potential association between specific cytokine patterns
and clinical response to GA were controversial primarily
due to the short follow-up period. A recent study with a
longer follow-up period of 3 years has demonstrated that150
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Figure 2 Th2/Th1 ratio in GA and NAT patients. Comparative Th2/Th1 ratios considering anti-inflammatory IL-4, IL-5, IL-6, IL-10 cytokines and
pro-inflammatory cytokine INF-γ (A) or TNF-α (B). Box and whiskers plots showing median and interquartile ranges are presented. IL-4/IFN-γ,
IL-4/TNF-α and IL-10/IFN-γ ratio as markers of Th2/Th1 ratio are significantly higher for GA patients compared to patients receiving NAT. *p < 0.05.
GA= glatiramer acetate; NAT = natalizumab.
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in those patients with RRMS that suffered from relapses
and progressing brain atrophy, suggesting that a specific
pattern of Th2/Th1 cytokines may predict clinical re-
sponse to GA therapy [33]. Moreover, this study suggests
that the quotient IL-4+ IL-10/IL-2+ IFN-γ could be a
promising parameter to identify patients associated with a
highly beneficial response to GA therapy. However, al-
though follow-up data over 3 years were available in this
study, the sample size was relatively small to draw firm
conclusions. Consequently, further studies including lar-
ger cohorts of patients will be required to validate that
clinical and immune response correlate in patients treated
with GA. Additionally, the mechanisms underlying the re-
lation between cytokine response and clinical outcome in
GA treated patients remain as a matter of debate.
The results of the present study show that patients
treated with NAT exhibit higher levels of circulating
proinflammatory cytokines and chemokines than those
treated with GA. These findings are in agreement with
previous studies where NAT treatment has been asso-
ciated with an increased expression of proinflammatory
cytokines in peripheral blood mononuclear cells [34,35].
Accordingly, an increase in activated leukocytes produ-
cing proinflammatory cytokines has been found in per-
ipheral blood of NAT-treated patients [34,36]. Although
it is not clear, these findings could probably be due to
the inhibition of transmigration of lymphocytes into
CNS, resulting in sequestration of activated T cells in
the peripheral circulation [36]. The prolonged T-cellactivation could result in decreased local immunosur-
veillance, reactivation of latent viral infections or oppor-
tunistic CNS infections, as evidenced by the rare but
severe occurrence of progressive multifocal leukoence-
phalopathy caused by JC virus in NAT-treated patients
[37]. Recent evidence has suggested that NAT seem to
exert its beneficial effect without affecting regulatory T
cell function [28]. Interestingly, NAT therapy has been
associated with an increase in some pro-inflammatory
and anti-inflammatory cytokines within the first
2 months of therapy, whereas relevant cytokines for MS
such as IL-2, IL-7, or IL-1β have been found to be
increased after one year of treatment, suggesting differ-
ent immunological mechanisms [28]. The changes in the
Th1/Th2 paradigm do not appear to be applicable to ex-
plain the beneficial effect of NAT. The increase of circu-
lating Th1 cytokines could be related to a “rebound”
effect that led to the development of new and enlarging
T2 lesions previously seen in cohorts of patients discon-
tinuing NAT due to safety issues related to this therapy,
particularly regarding PML [38]. This finding has led to
the concern that cessation of NAT might promote a
worsening of MS disease by increasing inflammatory ac-
tivity. The most likely explanation is that short exposure
to NAT (e.g., 2 infusions) results in blockade of migra-
tion and accumulation of activated lymphocytes in the
periphery that retain their capacity to cause CNS disease
[39].
The main limitations of this study include the small
sample size and a one-point measurement of cytokine
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are potentially interesting given that to our knowledge,
this is the first study to compare the Th1/Th2 bias be-
tween GA and NAT treated RRMS patients.
Conclusion
In summary, GA seems to modulate Th1/Th2 balance in
the systemic circulation with a shift toward the anti-
inflammatory Th2 profile response in RRMS patients.
This effect may have a beneficial effect on disease activ-
ity in these patients. Further studies including larger
cohorts of patients and a larger follow-up are needed in
order to establish whether this immune Th2 shift in GA
patients correlates with a favourable clinical response.
NAT seems to exert is beneficial effect through different
mechanisms than immunomodulators such as GA.
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